Department of Anesthesia and Intensive Care, Sahloul Academic Hospital, Sousse, Tunisia.
University of Medicine "Ibn Al Jazzar", Sousse, Tunisia.
Pain Res Manag. 2018 Jul 9;2018:9834059. doi: 10.1155/2018/9834059. eCollection 2018.
Gabapentinoids are increasingly used in preoperative premedication despite controversial results. The aim of our study was to evaluate the effects of preemptive use of gabapentin or pregabalin on postoperative shoulder pain and rehabilitation quality after laparoscopic cholecystectomy.
This is a clinical trial comparing the effects of a preoperative premedication with 600 mg of gabapentin or 150 mg of pregabalin versus placebo on postoperative pain and recovery quality after laparoscopic cholecystectomy. Premedication was taken 2 hours before the surgery beginning. Ninety patients were included and randomized into 3 groups (gabapentin, pregabalin, and placebo). The anesthetic protocol was the same for all patients. Primary endpoint was the shoulder pain intensity at the 48th postoperative hour. Secondary endpoints were postoperative nausea and vomiting (PONV), sleep quality during the first night, and the onset time for the first standing position.
During the first 48 postoperative hours, the gabapentin and pregabalin groups had significantly lower shoulder pain than the placebo group ( < 0.05). In gabapentinoids groups, the incidence of PONV was lower and the sleep quality during the first postoperative night was better with significant results. Mean Spiegel scores were 22.43 ± 1.45, 22.30 ± 1.44, and 17.17 ± 1.66, respectively, in pregabalin, gabapentin, and placebo groups ( < 0.05). The delay for the first standing position was 14.9 ± 4.9 hours in the pregabalin group, 9.7 ± 3.6 hours in the gabapentin group, and 21.6 ± 2.1 hours in the placebo group. No superiority was found between gabapentin and pregabalin.
Preemptive premedication with gabapentinoids can enhance postoperative rehabilitation quality after laparoscopic cholecystectomy by reducing postoperative shoulder pain, decreasing PONV incidence, and improving sleep quality during the first postoperative night. This trial is registered with ClinicalTrial.gov (NCT03241875).
尽管加巴喷丁类药物的使用存在争议,但它们在术前用药中仍被越来越多地使用。本研究的目的是评估预防性使用加巴喷丁或普瑞巴林对腹腔镜胆囊切除术术后肩部疼痛和康复质量的影响。
这是一项临床试验,比较了术前服用 600mg 加巴喷丁或 150mg 普瑞巴林与安慰剂对腹腔镜胆囊切除术后疼痛和康复质量的影响。术前用药在手术开始前 2 小时服用。共纳入 90 例患者,并随机分为 3 组(加巴喷丁组、普瑞巴林组和安慰剂组)。所有患者的麻醉方案相同。主要终点是术后 48 小时的肩部疼痛强度。次要终点是术后恶心呕吐(PONV)、第一晚睡眠质量和首次站立时间。
在术后的前 48 小时内,加巴喷丁组和普瑞巴林组的肩部疼痛明显低于安慰剂组(<0.05)。在加巴喷丁类药物组中,PONV 的发生率较低,第一晚术后睡眠质量较好,差异有统计学意义。普瑞巴林组、加巴喷丁组和安慰剂组的 Spiegel 评分分别为 22.43±1.45、22.30±1.44 和 17.17±1.66(<0.05)。普瑞巴林组首次站立时间为 14.9±4.9 小时,加巴喷丁组为 9.7±3.6 小时,安慰剂组为 21.6±2.1 小时。加巴喷丁和普瑞巴林之间没有优势。
预防性使用加巴喷丁类药物可以通过减轻术后肩部疼痛、降低 PONV 发生率和改善第一晚术后睡眠质量来提高腹腔镜胆囊切除术术后的康复质量。本试验在 ClinicalTrials.gov 注册(NCT03241875)。